MA72090B1 - Composés oxoisoindolinyl pipéridine-2,6-dione substitués - Google Patents

Composés oxoisoindolinyl pipéridine-2,6-dione substitués

Info

Publication number
MA72090B1
MA72090B1 MA72090A MA72090A MA72090B1 MA 72090 B1 MA72090 B1 MA 72090B1 MA 72090 A MA72090 A MA 72090A MA 72090 A MA72090 A MA 72090A MA 72090 B1 MA72090 B1 MA 72090B1
Authority
MA
Morocco
Prior art keywords
oxoisoindolinyl
dione
substitutes
piperidine
compounds
Prior art date
Application number
MA72090A
Other languages
English (en)
Inventor
John S. Tokarski
Andrew P. Degnan
Michael G. Yang
Zhonghui Lu
Vipin Yadav
James Kempson
Daniel Ferrante
Peter Kinam Park
Jinyi Zhu
Richard Charles BURRELL
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of MA72090B1 publication Critical patent/MA72090B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Sont divulgués des composés de formule (I) : (I) ou des stéréoisomères, tautomères ou sels de ceux-ci : R étant ; et le cycle A, L, R1, R2, R3, m et n étant tels que définis dans la description. Sont divulgués également des procédés d'utilisation de tels composés pour diminuer le niveau de la cycline E1 ; et des compositions pharmaceutiques comprenant de tels composés. Ces composés sont utiles dans le traitement de troubles prolifératifs, tels que le cancer.
MA72090A 2023-09-13 2024-09-12 Composés oxoisoindolinyl pipéridine-2,6-dione substitués MA72090B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363582266P 2023-09-13 2023-09-13
EP24782711.6A EP4587429B1 (fr) 2023-09-13 2024-09-12 Composés oxoisoindolinyl pipéridine-2,6-dione substitués
PCT/US2024/046299 WO2025059245A1 (fr) 2023-09-13 2024-09-12 Composés oxoisoindolinyl pipéridine-2,6-dione substitués

Publications (1)

Publication Number Publication Date
MA72090B1 true MA72090B1 (fr) 2026-03-31

Family

ID=92931770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA72090A MA72090B1 (fr) 2023-09-13 2024-09-12 Composés oxoisoindolinyl pipéridine-2,6-dione substitués

Country Status (25)

Country Link
US (1) US20250084056A1 (fr)
EP (1) EP4587429B1 (fr)
JP (1) JP7808733B2 (fr)
KR (1) KR20250068738A (fr)
CN (1) CN122422306A (fr)
AR (1) AR133800A1 (fr)
AU (1) AU2024342875A1 (fr)
CL (1) CL2026000568A1 (fr)
CO (1) CO2026002534A2 (fr)
DK (1) DK4587429T3 (fr)
ES (1) ES3066715T3 (fr)
FI (1) FI4587429T3 (fr)
HR (1) HRP20260405T1 (fr)
IL (1) IL327007A (fr)
LT (1) LT4587429T (fr)
MA (1) MA72090B1 (fr)
MX (1) MX2026002570A (fr)
PE (1) PE20260803A1 (fr)
PL (1) PL4587429T3 (fr)
PT (1) PT4587429T (fr)
RS (1) RS67970B1 (fr)
SI (1) SI4587429T1 (fr)
SM (1) SMT202600147T1 (fr)
TW (1) TW202525792A (fr)
WO (1) WO2025059245A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026112386A1 (fr) * 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Composés d'oxoisoindolinyl pipéridine-2,6-dione substitués et procédés de dégradation de protéines
CN120441535B (zh) * 2025-07-08 2025-09-30 苏州国匡医药科技有限公司 一种含炔基的gspt1降解剂及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CA2663057C (fr) 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles en tant que modulateurs d'indoleamine 2,3-dioxygenase
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (fr) 2007-10-05 2009-04-08 Immutep Utilisation de lag-3 recombinant ou ses dérivatifs pour déclencher la réponse immune des monocytes
WO2009073620A2 (fr) 2007-11-30 2009-06-11 Newlink Genetics Inhibiteurs de l'ido
EP2296789A1 (fr) 2008-05-29 2011-03-23 Saint-Gobain Centre de Recherches et d'Etudes Européen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (fr) 2009-09-03 2015-09-11 Merck Sharp & Dohme
EP2493862B1 (fr) 2009-10-28 2016-10-05 Newlink Genetics Corporation Dérivés imidazole comme inhibiteurs de l'ido
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (fr) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Anticorps se liant au csf1r
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
NO2694640T3 (fr) 2011-04-15 2018-03-17
CA2833636A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molecules qui se lient a b7-h1 et a pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
MX2020002010A (es) 2017-08-21 2020-07-13 Celgene Corp Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo.
WO2022152822A1 (fr) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Traitement de cancers entraînés par myc avec des agents de dégradation gspt1
WO2023059609A1 (fr) 2021-10-04 2023-04-13 Halda Therapeutics Opco, Inc. Composés hétérobifonctionnels et leur utilisation dans le traitement de maladies
WO2023069720A1 (fr) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Composés qui assurent la médiation de la dégradation de protéines et leurs procédés d'utilisation

Also Published As

Publication number Publication date
LT4587429T (lt) 2026-03-25
PE20260803A1 (es) 2026-04-08
AU2024342875A1 (en) 2026-04-30
MX2026002570A (es) 2026-04-01
ES3066715T3 (en) 2026-05-14
JP2026500094A (ja) 2026-01-06
AR133800A1 (es) 2025-11-05
PL4587429T3 (pl) 2026-05-18
WO2025059245A1 (fr) 2025-03-20
EP4587429B1 (fr) 2026-02-18
SMT202600147T1 (it) 2026-05-12
IL327007A (en) 2026-05-01
CL2026000568A1 (es) 2026-04-17
CN122422306A (zh) 2026-07-17
EP4587429A1 (fr) 2025-07-23
TW202525792A (zh) 2025-07-01
HRP20260405T1 (hr) 2026-05-08
KR20250068738A (ko) 2025-05-16
US20250084056A1 (en) 2025-03-13
SI4587429T1 (sl) 2026-06-30
CO2026002534A2 (es) 2026-03-16
RS67970B1 (sr) 2026-04-30
FI4587429T3 (fi) 2026-03-24
DK4587429T3 (da) 2026-03-30
PT4587429T (pt) 2026-03-20
JP7808733B2 (ja) 2026-01-29

Similar Documents

Publication Publication Date Title
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA54327B1 (fr) Inhibiteurs de kras g12c
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA55890B1 (fr) Modulateurs de thr-beta avec un groupe de tête dioxo-1,2,4-triazyl
MA31754B1 (fr) Cis-imidazolines chirales
MA54608B1 (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA47079B1 (fr) Composés amino-triazolopyidines et leur utilisation pour traiter le cancer
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA28747B1 (fr) Dérivés de pyridine
MA30403B1 (fr) Derives d'acides cycloalkylamines et leurs compositions pharmaceutiques
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA30532B1 (fr) Sulfonamides tricycliques condenses inhibiteurs de gamma-secretase
TN2014000115A1 (fr) Derives de pyrrolopyrimidines et de purines
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
TN2009000450A1 (fr) Derives de pyridine
MA28094A1 (fr) Dérivés [3.1.0] bicycliques servant d'inhibiteurs du transporteur de glycine
MA27764A1 (fr) Acides carboxyliques alpha-substitués servant de modulateurs de PPAR
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA29926B1 (fr) Derives de pyrazine
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA57000B1 (fr) Dérivés d'alpha-d-galactopyranoside
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.